Validating targets antiparasitic chemotherapy

Addressing parasitic diseases and those caused by bacteria, this much needed reference and handbook provides a unique insight into the approach adopted by commercial science towards infectious diseases, including the work of medicinal chemists.Many of the authors are scientists with hands-on experience of drug discovery units within the pharmaceutical industry.

validating targets antiparasitic chemotherapy-12validating targets antiparasitic chemotherapy-64validating targets antiparasitic chemotherapy-88

Malaria parasite has a complex life cycle [3] and transmitted to human by the bite of an infected female mosquito of the genus anopheles which harbours the parasite [5].

The enzymes and receptors in parasites that can be qualified as targets for antiparasite chemotherapy should perform essential functions in the parasites and demonstrate some feasibility for selective inhibition.

Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising chances of success.

One sixth of the world’s population - approximately 1 billion people - are infected with neglected tropical diseases (NTDs) including the vector-borne parasitic diseases, African sleeping sickness, Chagas disease, leishmaniasis, filariasis, onchocerciasis and schistosomiasis [1].

In addition, the text covers efforts towards drug development in infectious diseases from academic groups and non profit organizations.

Preamble Editor Preface PART I Drug Discovery Approaches 1 Target identification and mechanism-based screening for anthelmintics: Application of veterinary antiparasitic research programmes to search for new antiparasitic drugs for human indications 2 Anthelmintic resistance as a guide to the discovery of new drugs? Selzer studied Biology, Parasitology, and Biochemistry at the University of Tbingen, Germany, where he also received his Ph D in Biochemistry on subjects related to the protozoan parasite Trypanosoma brucei.

To ensure any drug discovery project is addressing the requirements of the patients and health care providers and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set of criteria called a target product profile.

Using a target product profile the drug discovery process, clinical study design, and compound characteristics can be defined all the way back through to the suitability or druggability of the intended biochemical target.

Modern advancement in the biology of the parasite and different genomic techniques provide wide ranges of novel targets in the development of new therapy.

Tags: , ,